PCA
KPTI icon

Providence Capital Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Providence Capital Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-21
Closed -$271 – 362
2024
Q2 		$271 Hold
21
– – ﹤0.01% 344
2024
Q1 		$471 Buy
+21
New +$368 ﹤0.01% 327

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Providence Capital Advisors's KPTI Position: Q3 2024 in Review

Providence Capital Advisors sold out of Karyopharm Therapeutics (KPTI) in Q3 2024, closing a stake of 21 shares — an estimated $271 sold.

Providence Capital Advisors first reported a position in KPTI in Q1 2024 and held it in 2 quarters. The position peaked at $471 in Q1 2024. 91 funds tracked by Wall St. Rank hold KPTI as of Q3 2024.

  • Providence Capital Advisors reported no remaining Karyopharm Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Providence Capital Advisors sold 21 Karyopharm Therapeutics shares in Q3 2024, an estimated $271.
  • Providence Capital Advisors first reported a position in Karyopharm Therapeutics in Q1 2024 and held it in 2 quarters.
  • Providence Capital Advisors's Karyopharm Therapeutics position peaked at $471 in Q1 2024.
  • 91 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2024.

Based on Providence Capital Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.